Probity Advisors’s Takeda Pharmaceutical TAK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $639K | Buy |
41,328
+2,377
| +6% | +$36.7K | 0.11% | 129 |
|
|
2025
Q1 | $579K | Sell |
38,951
-4,344
| -10% | -$64.6K | 0.11% | 133 |
|
|
2024
Q4 | $573K | Sell |
43,295
-1
| -0% | -$13 | 0.11% | 127 |
|
|
2024
Q3 | $616K | Buy |
43,296
+3,661
| +9% | +$52.1K | 0.12% | 130 |
|
|
2024
Q2 | $513K | Buy |
39,635
+14,856
| +60% | +$192K | 0.11% | 141 |
|
|
2024
Q1 | $344K | Buy |
24,779
+3,001
| +14% | +$41.7K | 0.07% | 176 |
|
|
2023
Q4 | $311K | Buy |
21,778
+4,290
| +25% | +$61.2K | 0.07% | 178 |
|
|
2023
Q3 | $271K | Buy |
17,488
+2,853
| +19% | +$44.1K | 0.06% | 162 |
|
|
2023
Q2 | $230K | Buy |
+14,635
| New | +$230K | 0.05% | 175 |
|
|
2022
Q4 | $196K | Buy |
12,548
+455
| +4% | +$7.1K | 0.04% | 179 |
|
|
2022
Q3 | $157K | Buy |
+12,093
| New | +$157K | 0.04% | 169 |
|